A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For some, obesity is primarily driven by insulin ... obesity care. GLP Compass – Provides members with clarity on their weight loss journey by determining who truly needs GLP-1 drugs versus ...

The purpose of the present study was to assess the effect of GLP-1, administered in combination with the thiazolidinedione, pioglitazone, on glucose, insulin, glucagon, free fatty acids (FFAs ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition ...

The company will prioritize insulin deficient patients and combination strategies with GLP-1-based therapies for obesity and diabetes. Biomea plans to conclude its studies exploring icovamenib’s ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.